AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous infusion pump ...
VYALEV, also known as PRODUODOPA, is the first and only subcutaneous ... 2,400mg foslevodopa per 10ml solution dose. AbbVie ...